BREAKING--Clinical Rationale for SARS-CoV-2 Base Spike Protein Detoxification in Post COVID-19 and Vaccine Injury Syndromes

Publication of Baseline Protocol for Those Suffering from Long-COVID and Post-Acute Sequelae after COVID-19 Vaccination

By Peter A. McCullough

For several weeks I have been messaging the scientific community and the public about an approach addressing the burden of SARS-CoV-2 Spike protein in tissues and organs in the human body that is largely responsible for post-COVID and vaccine injury syndromes.

No therapeutic claims can be made since large, prospective, double-blind randomized, placebo-controlled trials have not been completed on any of the compounds mentioned in this paper. I checked clinicaltrials.gov and no such trials have been planned. The Biden HHS US Action Plan for Long-COVID Research has pumped a billion dollars into long-COVID research and no new therapies have emerged. HHS, NIH, CDC, FDA have not recognized the larger issue of vaccine damage to the body.

At three and one half years into the pandemic and two and a half years into the COVID-19 vaccine debacle, myself and my clinic partners formulated a baseline regimen upon which additional drugs or agents can be added. We believe the Spike protein and the inflammation cause by it and its proteolytic fragments are at the heart of the pathophysiology we are observing.

We searched the literature for all available sources of evidence for products that can aid the human body in breaking down and catabolizing the Spike protein. We found two compounds, nattokinase and bromelain. Both of which additionally have fibrinolytic properties which are advantageous in the prothrombotic milieu induced by the persistent Spike protein. Curcumin was added for its anti-inflammatory properties in the setting of post-COVID and vaccine patients. The main safety caveats are bleeding and allergic reactions, both of which are manageable. It is our experience that both nattokinase and bromelain can be used in addition to antiplatelet and anticoagulant drugs with physician monitoring.

The empiric regimen can be continued for 3-12 months or more and be guided by clinical observation:

-Nattokinase 2000 FU (100) mg orally twice a day without food

-Bromelain 500 mg orally once a day without food

-Curcumin 500 mg orally twice a day (nano, liposomal, or with piperine additive suggested)

McCullough PA, Wynn C, Procter BC. Clinical Rationale for SARS-CoV-2 Base Spike Protein Detoxification in Post COVID-19 and Vaccine Injury Syndromes. Journal of American Physicians and Surgeons Volume 28 Number 3 Fall 2023, 90-93.

The full manuscript is linked and serves as your reference. While we are seeing case examples of improvement, we aim to collaborate with others as we did with the McCullough Protocol, to demonstrate clinical effectiveness of Base Spike Detoxification as a fundamental strategy for a large number of individuals who have suffered long-term consequences from SARS-CoV-2 infection and COVID-19 vaccination.

Please subscribe to Courageous Discourse as a paying or founder member so we can continue to bring you the truth.

Peter A. McCullough, MD, MPH

President, McCullough Foundation

www.mcculloughfnd.org

McCullough PA, Wynn C, Procter BC. Clinical Rationale for SARS-CoV-2 Base Spike Protein Detoxification in Post COVID-19 and Vaccine Injury Syndromes. Journal of American Physicians and Surgeons Volume 28 Number 3 Fall 2023, 90-93.

McCullough, Peter A, Wynn, Cade, & Procter, Brian C. (2023). Clinical Rationale for SARS-CoV-2 Base Spike Protein Detoxification in Post COVID-19 and Vaccine Injury Syndromes. Journal of American Physicians and Surgeons, 28(3), 90–94. https://doi.org/10.5281/zenodo.8286460